title: New viruses for cancer therapy: meeting clinical needs.
abstract: Early-stage clinical trials of oncolytic virotherapy have reported the safety of several virus platforms, and viruses from three families have progressed to advanced efficacy trials. In addition, preclinical studies have established proof-of-principle for many new genetic engineering strategies. Thus, the virotherapy field now has available a diverse collection of viruses that are equipped to address unmet clinical needs owing to improved systemic administration, greater tumour specificity and enhanced oncolytic efficacy. The current key challenge for the field is to develop viruses that replicate with greater efficiency within tumours while achieving therapeutic synergy with currently available treatments.
authors.affiliation: 1] Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. [2] Virology and Gene Therapy Track, Mayo Graduate School, Rochester, Minnesota 55905, USA.
authors.forename: Tanner S
authors.initials: TS
authors.lastname: Miest
authors.affiliation: 1] Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. [2] Virology and Gene Therapy Track, Mayo Graduate School, Rochester, Minnesota 55905, USA.
authors.forename: Roberto
authors.initials: R
authors.lastname: Cattaneo
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D005818:Genetic Engineering; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D050130:Oncolytic Virotherapy / Q000379:methods*; D014780:Viruses / Q000145:classification* / Q000235:genetics*